The non-small cell lung cancer clinical trial analysis report delivers important insights into ongoing research of 120+ ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...
Canadians swallow millions of pills every day to treat common health issues like high blood pressure, high cholesterol and ...
A few transplant patients in a small study were able to stop using immunosuppressive drugs, thanks to pre-transplant cell ...
McGill University researchers have developed an artificial intelligence tool that can identify small groups of cells most ...
Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and ...
McGill University researchers have developed an artificial intelligence tool that can identify small groups of cells most responsible for driving aggressive cancers. The tool, called SIDISH, offers ...
First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...
The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...
A man in Norway has achieved long-term HIV remission after a stem cell transplant from his brother. Researchers say rare ...
Firefighters in York County say a cell phone left unattended on a bed overheated and caused a small fire, triggering an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results